MOTCO’s Acadia Pharmaceuticals ACAD Stock Holding History

MOTCO’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.1K	Buy	+800	New	+$21.5K	﹤0.01%	449

Other funds holding ACAD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

MOTCO's ACAD Position: Q3 2026 in Review

MOTCO opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 800 shares worth $16.1K. The stake represents ﹤0.01% of the portfolio and ranks #449 among its holdings.

179 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

MOTCO held 800 shares of Acadia Pharmaceuticals worth $16.1K as of Q3 2026.
Acadia Pharmaceuticals was a new MOTCO position in Q3 2026.
Acadia Pharmaceuticals made up ﹤0.01% of MOTCO's portfolio in Q3 2026, its #449 holding.
179 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on MOTCO's 13F filing for Q3 2026, filed 9 Nov 2026.